Site Map
Back
  • Home
  • What is BPS?
    • Bladder pain syndrome (BPS)
    • ESSIC classification
    • BPS impact on quality of life
  • About elmiron®
    • What is elmiron®?
    • elmiron® in the treatment of BPS
    • elmiron® HTA assessments
    • elmiron® efficacy data
    • elmiron® tolerability
    • How to prescribe elmiron® and safety considerations
  • Resource centre
    • elmiron® regulatory documents
    • Health technology assessments
    • Medical society guidelines
    • Downloadable resources
    • Relevant publications
  • Report side effects
  • Prescribing information

Healthcare professional section

  • Home
  • What is BPS?
  • About elmiron®
  • Resource centre
  • Prescribing information
  • Report side effects

Footer section

  • Privacy Policy
  • Legal Notice
  • Cookies
  • Site Map
  • Contact Us
  • Prescribing information

Date of preparation: July 2020 UK-ELM-111g
Copyright ©2020 Consilient Health Ltd. All rights reserved.

Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Consilient Health (UK) Ltd, No. 1 Church Road, Richmond upon Thames, Surrey TW9 2QE UK or drugsafety@consilienthealth.com

  • Privacy Policy
  • Legal Notice
  • Cookies
  • Site Map
  • Contact Us
  • Prescribing information

Date of preparation August 2022 UK-ELM-111j(1)

This site is intended for
Healthcare Professionals registered in the UK.

Continue Cancel

By clicking CONTINUE you are confirming that you are a
Healthcare Professional registered in the UK.

Date of preparation May 2021  UK-ELM-111k

You are now leaving this webpage. Any information derived from an external link is not owned by Consilient Health and is not subject to any Consilient Health policy.

This link does not constitute endorsement by Consilient Health.

Do you wish to continue?

Yes No